Inhibiting Viral Infection Using Alternating Electric Fields

ABSTRACT

Viral infections in a target region can be inhibited by imposing an alternating electric field in the target region for a duration of time. The alternating electric field has a frequency and a field strength such that when the alternating electric field is imposed in the target region for the duration of time, the alternating electric field inhibits infection of the cells in the target region by the virus. Optionally, the inhibition of viral infections using the alternating electric field approach can be combined with delivering an antiviral agent to the target region so that a therapeutically effective dose of the antiviral agent is present in the target region while the alternating electric fields are imposed.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application62/695,925, filed Jul. 10, 2018, which is incorporated herein byreference in its entirety.

BACKGROUND

Viruses are small intracellular obligate parasites. Viruses include anucleic acid that contains the genetic information necessary to programthe synthetic machinery of the host cell for viral replication, and, inthe simplest viruses, a protective protein coat.

To infect a cell, the virus must attach to the cell surface, penetrateinto the cell, and become sufficiently uncoated to make its genomeaccessible to viral or host machinery for transcription or translation.Viruses' multiplication usually causes cell damage or death. Productiveinfection results in the formation of progeny viruses.

It has previously been shown that when cells are exposed to analternating electric field (AEF) in specific frequency ranges while thecell is undergoing mitosis, the AEF can disrupt the mitosis process andcause apoptosis. This phenomenon has been successfully used to treattumors (e.g. glioblastoma, mesothelioma, etc.) as described in U.S. Pat.Nos. 7,016,725 and 7,565,205, each of which is incorporated herein byreference in its entirety. And in the context of treating tumors, thesealternating electric fields are referred to as “TTFields” (or “TumorTreating Fields”). One of the reasons why TTFields therapy iswell-suited for treating tumors is that TTFields selectively disruptdividing cells during mitosis, and apparently have no effect on cellsthat are not dividing. And because tumor cells divide much more oftenthan other cells in a person's body, applying TTFields to a subject willselectively attack the tumor cells while leaving the other cellsunharmed. The same phenomenon has also been successfully shown to beuseful for destroying bacteria, as described in U.S. Pat. No. 9,750,934,which is incorporated herein by reference in its entirety. And hereagain, one of the reasons why this approach is well-suited fordestroying bacteria is that bacteria cells divide much more rapidly thanother cells in a person's body.

SUMMARY OF THE INVENTION

One aspect of the invention is directed to a first method of inhibitinga virus from infecting cells in a target region. The first methodcomprises the steps of imposing an alternating electric field in thetarget region for a duration of time, the alternating electric fieldhaving a frequency and a field strength, wherein when the alternatingelectric field is imposed in the target region for the duration of time,the alternating electric field inhibits infection of the cells in thetarget region by the virus.

In some instances of the first method, the target region is a regionwithin a live subject, and the alternating electric field is safe forthe subject. In some of these instances, the target region istumor-free.

In some instances of the first method, the target region is a regionwithin a live subject, the alternating electric field is safe for thesubject, and the first method further comprises the step of deliveringan antiviral agent to the target region so that a therapeuticallyeffective dose of the antiviral agent is present in the target regionwhile the imposing is performed.

Some instances of the first method further comprise the step ofdelivering an antiviral agent to the target region so that the antiviralagent is present in the target region while the imposing is performed.

In some instances of the first method, the alternating electric fieldhas a frequency between 50 and 500 kHz. In some instances of the firstmethod, the alternating electric field has a frequency between 25 kHzand 1 MHz. In some instances of the first method, the alternatingelectric field has a frequency of about 200 kHz.

In some instances of the first method, the alternating electric fieldhas a field strength between 1 and 5 V/cm RMS. In some instances of thefirst method, the alternating electric field has a field strength ofabout 1.2 V/cm RMS.

In some instances of the first method, the duration of time is between 1and 48 hours. In some instances of the first method, the duration oftime is between 2 and 14 days. In some instances of the first method,the duration of time is about 48 hours.

In some instances of the first method, the alternating electric fieldhas an orientation that is repeatedly switched between at least twodirections during the duration of time. In some of these instances, theorientation of the alternating electric field is switched about once asecond.

In some instances of the first method, the alternating electric fieldhas an orientation that is repeatedly switched between a first directionand a second direction during the duration of time, and the firstdirection is roughly perpendicular to the second direction.

In some instances of the first method, the alternating electric field isapplied to the target region via capacitively coupled electrodes.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of a dish that was used for two invitro experiments.

FIG. 2 is a schematic representation of an AC voltage generator that isused to apply AC voltages to the electrodes in the various embodimentsdescribed herein.

FIG. 3 depicts the relative infection efficiency with respect to thecontrol for a first experiment.

FIG. 4 depicts the relative infection efficiency with respect to thecontrol for a second experiment.

FIGS. 5A and 5B depict front and back views, respectively, forpositioning electrodes on a subject's body in an exemplary embodiment.

Various embodiments are described in detail below with reference to theaccompanying drawings, wherein like reference numerals represent likeelements.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Surprisingly, the inventors have shown that alternating electric fieldscan also be used to inhibit viral infections. These results aresurprising because AEF operates in the contexts described above bydisrupting dividing cells during mitosis. But unlike tumor cells andbacteria, viruses do not replicate by mitosis.

Two in vitro experiments establishing that AEFs can inhibit viralinfection will now be described. These experiments used a Novocure™Inovitro™ test setup to measure Lentiviral infection of human embryonickidney HEK293FT cells obtained from ThermoFisher Scientific.

The Inovitro™ test setup includes eight dish-shaped containers, each ofwhich is shaped and dimensioned for holding a culture, and FIG. 1 is aschematic representation of a representative one of these dishes. Eachdish 30 includes ceramic sidewalls 31 and a bottom panel 32 that, takentogether, form the dish. A plurality of electrodes 41-44 is disposed onthe outer surface of the ceramic sidewalls 31 at positions selected sothat when a culture is positioned in the container, application of avoltage between the plurality of electrodes 41-44 induces an electricfield through the culture. More specifically, (a) application of an ACvoltage between electrodes 41 and 42 induces an alternating electricfield in a first direction through the culture, and (b) application ofan AC voltage between electrodes 43 and 44 induces an alternatingelectric field in a second direction through the culture. In the FIG. 1embodiment, the second direction is perpendicular to the first directiondue to the placement of the electrodes 41-44 on the ceramic sidewalls31. Note that if one subset of electrodes (e.g. electrodes 41 and 42)were to be shifted by a small angle (e.g. less than 10°), the seconddirection would be roughly perpendicular to the first direction.

Turning now to FIG. 2, an AC voltage generator 20 generates signals thatare applied to the first pair of electrodes 41, 42 and the second pairof electrodes 43, 44. The AC voltage generator 20 applies an AC voltageat a selected frequency between the first pair of electrodes 41, 42 forone second, then applies an AC voltage at the same frequency between thesecond pair of electrodes 43, 44 for one second, and repeats this twostep sequence for the duration of the experiment. The system alsoincludes thermal sensors (not shown), and the AC voltage generator 20will decrease the amplitude of the AC voltages that are being applied tothe electrodes if the sensed temperature of the dish 30 gets too high.

In the first experiment, the kidney cells were exposed to a lentivirusthat encodes for a Green Fluorescent Protein (GFP). For this experiment,a Dharmacon™ Trans-Lentiviral Packaging Kit with Calcium PhosphateTransfection Reagent TLP5916 and Precision LentiORF RFP Control DNAOHS5832 were used. The Multiplicity of Infection was 5, and 200 kHz AEFswith a field strength of 1.2 V/cm RMS were applied to the culture for 48hours. The direction of the AEFs was switched every second as describedabove. A control was subjected to the exact same conditions except thatthe AEFs were not applied. At the end of the 48 hour period, infectedcells were identified based on the presence of GFP (i.e., the presenceof GFP means that the cell was infected). Infection efficiency wasmeasured by flow cytometry analysis as the % of cells expressing theviral-encoded GFP. The percentage of infected cells in the AEF treatedculture was 30%; and the percentage of infected cells in the controlculture was 47%. Relative infection efficiency (with respect to thecontrol) was then calculated. The results, which are depicted in FIG. 3,were as follows: for the 200 kHz AEFs, the relative infection level was64±0.5% as compared to the control cells (100±5.4%, p<0.01, student Ttest).

At the end of the 48 hour period, observation revealed that the cellswere dividing during the course of the experiment for both the AEFtreated cultures and the control; and that there was no significanteffect on the total number of cells as between the AEF treated culturesand the control. One possible explanation for this may be the relativelyshort (48 hour) treatment duration combined with the low field intensitythat was used, since the AEFs could be applied in no less than 27° C.

The second in vitro experiment was identical to the first experiments inall respects except that a 100 kHz AEF was used in place of the 200 kHzAEF that was used in the first experiment. The results of this secondexperiment were as follows: The percentage of infected cells in the AEFtreated culture was 51%; and the percentage of infected cells in thecontrol culture was 64%. Relative infection efficiency (with respect tothe control) was then calculated. The results, which are depicted inFIG. 4, were as follows: for the 100 kHz AEFs, the relative infectionlevel was 80±2% as compared to the control cells (100±3.7%, p<0.01p<0.0005, student T test).

In the two in vitro experiments described above, the frequency of theAEFs was either 100 or 200 kHz. But in alternative embodiments, thefrequency of the AEFs could be another frequency between 50 and 500 kHz.In other embodiments, the frequency of the AEFs could be between 25 kHzand 1 MHz. In other embodiments, the frequency of the AEFs could bebetween 1 and 10 MHz. In still other embodiments, the frequency of theAEFs could be between 10 and 100 MHz. The optimal frequency may bedetermined experimentally for each combination of a given type of hostcell and a given type of virus that is either infecting or attempting toinfect the host cells, depending on the intended use. Preferably, careis taken to ensure that the frequency selected does not adversely heatthe target region.

In the two in vitro experiments described above, the field strength ofthe AEFs was 1.2 V/cm RMS. But in alternative embodiments, a differentfield strength may be used (e.g., between 0.2 and 1 V/cm RMS, between 1and 5 V/cm RMS, or between 5 and 25 V/cm RMS. The optimal field strengthmay be determined experimentally for each combination of a given type ofhost cell and a given type of virus that is either infecting orattempting to infect the host cells, depending on the intended use.

In the two in vitro experiments described above, the AEFs were appliedfor 48 hours. But in alternative embodiments, a different duration maybe used (e.g., between 1 and 48 hours, or between 2 and 14 days). Insome embodiments, application of the AEFs may be repeated periodically.For example, the AEFs may be applied every day for a two hour duration.

In the two in vitro experiments described above, the direction of theAEFs was switched at one second intervals between two perpendiculardirections. But in alternative embodiments, the direction of the AEFscan be switched at a faster rate (e.g., at intervals between 1 and 1000ms) or at a slower rate (e.g., at intervals between 1 and 100 seconds).

In the two in vitro experiments described above, the direction of theAEFs was switched between two perpendicular directions by applying an ACvoltage to two pairs of electrodes that are disposed 90° apart from eachother in 2D space in an alternating sequence. But in alternativeembodiments the direction of the AEF may be switched between twodirections that are not perpendicular by repositioning the pairs ofelectrodes, or between three or more directions (assuming thatadditional pairs of electrodes are provided). For example, the directionof the AEFs may be switched between three directions, each of which isdetermined by the placement of its own pair of electrodes. Optionally,these three pairs of electrodes may be positioned so that the resultingfields are disposed 90° apart from each other in 3D space. In otheralternative embodiments, the electrodes need not be arranged in pairs.See, for example, the electrode positioning described in U.S. Pat. No.7,565,205, which is incorporated herein by reference. In otheralternative embodiments, the direction of the field need not be switchedat all, in which case the second pair of electrodes 43, 44 (shown inFIG. 1) can be omitted.

In the two in vitro experiments described above, the electrical fieldwas capacitively coupled into the culture because the conductiveelectrodes 41-44 were disposed on the outer surface of the ceramicsidewalls 31, and the ceramic material of the sidewalls 31 acts as adielectric. But in alternative embodiments, the electric field could beapplied directly to the culture without capacitive coupling (e.g., bymodifying the configuration depicted in FIG. 1 so that the conductiveelectrodes are disposed on the sidewall's inner surface instead of onthe sidewall's outer surface).

In the two in vitro experiments described above, human embryonic kidneyHEK293FT cells were positioned in a target region within a dish 30(shown in FIG. 1), and a lentivirus was used to infect those cells.Imposing the alternating electric field in the target region inhibitedinfection of the cells in the target region by the virus. In alternativeembodiments, different cell types and/or different virus types may beused.

These results can be applied to the in vivo context by applying the AEFsto a target region of a live subject's body. Imposing the alternatingelectric field in the target region will inhibit infection of the cellsin the target region by the virus. This may be accomplished, forexample, by positioning electrodes on the subject's skin orsubcutaneously so that application of an AC voltage between selectedsubsets of those electrodes will impose the AEF in the target region ofthe subject's body. For example, in situations where the virus at issuetypically colonizes the lungs, the electrodes 51-54 could be positionedas depicted in FIGS. 5A and 5B. In some embodiments, the electrodes arecapacitively coupled to the subject's body (e.g., by using electrodesthat include a conductive plate and also have a dielectric layerdisposed between the conductive plate and the subject's body). But inalternative embodiments, the dielectric layer may be omitted, in whichcase the conductive plates would make direct contact with the subject'sbody.

The AC voltage generator 20 (shown in FIG. 2) applies an AC voltage at aselected frequency (e.g. 200 kHz) between the first pair of electrodes51, 52 for a first period of time (e.g. 1 second), which induces an AEFwhere the most significant components of the field lines are parallel tothe transverse axis of the subject's body. Then, the AC voltagegenerator 20 applies an AC voltage at the same frequency (or a differentfrequency) between the second pair of electrodes 53, 54 for a secondperiod of time (e.g. 1 second), which induces an AEF where the mostsignificant components of the field lines are parallel to the sagittalaxis of the subject's body. This two step sequence is then repeated forthe duration of the treatment. Optionally, thermal sensors (not shown)may be included at the electrodes, and the AC voltage generator 20 canbe configured to decrease the amplitude of the AC voltages that areapplied to the electrodes if the sensed temperature at the electrodesgets too high. In some embodiments, one or more additional pairs ofelectrodes may be added and included in the sequence. For example, whenthe additional pair of electrodes 55, 56 shown in FIGS. 5A and 5B areadded, and the AC voltage generator 20 applies an AC voltage to thoseelectrodes, it would induce an AEF where the most significant componentsof the field lines are parallel to the longitudinal axis of thesubject's body. Note that any of the parameters for this in vivoembodiment (e.g., frequency, field strength, duration,direction-switching rate, and the placement of the electrodes) may bevaried as described above in connection with the in the vitroembodiment. But care must be taken to ensure that the alternatingelectric field remains safe for the subject at all times.

In the in vivo context, the AEFs may be applied to a target region(e.g., the lungs of a first person) that is tumor free. Alternatively,the AEFs may be applied to a target region that contains a tumor (e.g.,the lungs of a different person).

In any of the embodiments described above, the application of AEFs maybe combined with delivering an antiviral agent to the target region sothat a therapeutically effective dose of the antiviral agent is presentin the target region while the imposing of the AEF is performed.

Because AEFs can inhibit viral infection, applying AEFs can prevent thedamage made by infection of new cells (alteration of cell's functions,cell death or transformation), stop viral multiplication and spread, andavoid its ramifications on the wellbeing of the infected person.

AEF-based anti-viral therapy may also be used for the protection ofuninfected healthy individuals from a threatening infection, like in thecase of medical staff that come into close contact with infectedindividuals (especially in acute phases of viral diseases wheninfectious particles may be found in blood, skin lesions, saliva etc.,and can be transmitted by direct or indirect contact, e.g., via dropletsor aerosols).

AEF-based anti-viral protection may also be used by individuals withsuppressed immune system (like in cases of congenital immunodeficiency,organ transplant, cancer etc.), which lack the natural forceful defenseof the body, hence are extremely sensitive to opportunistic infections.

Additionally, inhibition of viral infection could be of enormousimportance to the progression of an ongoing viral disease. Humanimmunodeficiency virus (HIV) is an example for a virus that remainsclinically dormant in the human body for a long period of time, however,during this period the virus persists and replicates, particularly inlymph nodes. Over time the number of the susceptible immune cellsdecline following infection and AIDS (Acquired Immune DeficiencySyndrome) develops. Halting the continuous cycles of viral infectionwould seize the spread within and prevent the progression of thedisease.

Furthermore, AEF-based anti-viral therapy could potentially show evenhigher effect if combined with additional anti-viral drugs.

While the present invention has been disclosed with reference to certainembodiments, numerous modifications, alterations, and changes to thedescribed embodiments are possible without departing from the sphere andscope of the present invention, as defined in the appended claims.Accordingly, it is intended that the present invention not be limited tothe described embodiments, but that it has the full scope defined by thelanguage of the following claims, and equivalents thereof.

What is claimed is:
 1. A method of inhibiting a virus from infectingcells in a target region, comprising the steps of: imposing analternating electric field in the target region for a duration of time,the alternating electric field having a frequency and a field strength,wherein when the alternating electric field is imposed in the targetregion for the duration of time, the alternating electric field inhibitsinfection of the cells in the target region by the virus.
 2. The methodof claim 1, wherein the target region is a region within a live subject,and wherein the alternating electric field is safe for the subject. 3.The method of claim 2, wherein the target region is tumor-free.
 4. Themethod of claim 2, further comprising the step of delivering anantiviral agent to the target region so that a therapeutically effectivedose of the antiviral agent is present in the target region while theimposing is performed.
 5. The method of claim 1, further comprising thestep of delivering an antiviral agent to the target region so that theantiviral agent is present in the target region while the imposing isperformed.
 6. The method of claim 1, wherein the alternating electricfield has a frequency between 50 and 500 kHz.
 7. The method of claim 1,wherein the alternating electric field has a frequency between 25 kHzand 1 MHz.
 8. The method of claim 1, wherein the alternating electricfield has a frequency of about 200 kHz.
 9. The method of claim 1,wherein the alternating electric field has a field strength between 1and 5 V/cm RMS.
 10. The method of claim 1, wherein the alternatingelectric field has a field strength of about 1.2 V/cm RMS.
 11. Themethod of claim 1, wherein the duration of time is between 1 and 48hours.
 12. The method of claim 1, wherein the duration of time isbetween 2 and 14 days.
 13. The method of claim 1, wherein the durationof time is about 48 hours.
 14. The method of claim 1, wherein thealternating electric field has an orientation that is repeatedlyswitched between at least two directions during the duration of time.15. The method of claim 14, wherein the orientation of the alternatingelectric field is switched about once a second.
 16. The method of claim1, wherein the alternating electric field has an orientation that isrepeatedly switched between a first direction and a second directionduring the duration of time, wherein the first direction is roughlyperpendicular to the second direction.
 17. The method of claim 1,wherein the alternating electric field is applied to the target regionvia capacitively coupled electrodes.